Back to Publications
August, 2021
MORNINGSKY Trial
BlueClinical is involved, through its Clinical Research Partnership Network, on the Phase 3 MORNINGSKY trial
BlueClinical is involved, through its Clinical Research Partnership Network, on the Phase 3 MORNINGSKY trial, a global multicenter study evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting.
Learn more at https://www.covid19morningsky.com/PT
Other Publication
BlueClinical recognized by Agência Nacional de Inovação (ANI)
BlueClinical recognized by Agência Nacional de Inovação (ANI) as an idoneous entity for conducting R&D activities in the field of translational research
BlueClinical is a founding member of the new pan-European CRO Astrum.
BlueClinical is a founding member of the new pan-European CRO Astrum. For more information about the new range of available services, visit the new Company's website at www.astrumcro.com.
